Allarity Therapeutics, Inc. Paid-in-Kind Interest
Allarity Therapeutics, Inc. (ALLR) reported Paid-in-Kind Interest of $886.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-14
- Allarity Therapeutics, Inc. paid-in-kind interest for the quarter ending 2026-06-30 was $790.00K, a 2223.53% increase year-over-year.
- Allarity Therapeutics, Inc. paid-in-kind interest for the quarter ending 2026-03-31 was $96.00K, a 65.52% increase year-over-year.
- Allarity Therapeutics, Inc. paid-in-kind interest for the quarter ending 2025-12-31 was $19.00K, a 66.67% decline year-over-year.
- Allarity Therapeutics, Inc. paid-in-kind interest for the quarter ending 2025-09-30 was $74.00K, a 29.82% increase year-over-year.
- Allarity Therapeutics, Inc. paid-in-kind interest for fiscal 2025 was $185.00K, a 19.57% decline from fiscal 2024.
- Allarity Therapeutics, Inc. paid-in-kind interest for fiscal 2024 was $230.00K, a 50.43% decline from fiscal 2023.
- Allarity Therapeutics, Inc. paid-in-kind interest for fiscal 2023 was $464.00K, a 236.23% increase from fiscal 2022.
- Allarity Therapeutics, Inc. paid-in-kind interest for fiscal 2022 was $138.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 9 month as first filed | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $790.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $886.00K 10-Q · filed 2026-08-14 | $905.00K derived: sum of 3 quarters · filed 2026-08-14 | $979.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $96.00K 10-Q · filed 2026-05-15 | $115.00K derived: sum of 2 quarters · filed 2026-05-15 | $189.00K derived: sum of 3 quarters · filed 2026-05-15 | $223.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $93.00K derived: sum of 2 quarters · filed 2026-03-30 | $127.00K derived: sum of 3 quarters · filed 2026-08-14 | $185.00K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $108.00K derived: sum of 2 quarters · filed 2026-08-14 | $166.00K 10-Q · filed 2025-11-14 | $223.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $92.00K 10-Q · filed 2026-08-14 | $149.00K derived: sum of 3 quarters · filed 2026-08-14 | $206.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $58.00K 10-Q · filed 2026-05-15 | $115.00K derived: sum of 2 quarters · filed 2026-05-15 | $172.00K derived: sum of 3 quarters · filed 2026-05-15 | $192.00K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $114.00K derived: sum of 2 quarters · filed 2026-03-30 | $134.00K derived: sum of 3 quarters · filed 2026-03-30 | $230.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $77.00K derived: sum of 2 quarters · filed 2025-11-14 | $173.00K 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2024-11-14 | -$473.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $116.00K 10-Q · filed 2025-08-15 | -$530.00K derived: sum of 3 quarters · filed 2025-08-15 | $380.00K derived: sum of 4 quarters · filed 2025-08-15 | |
| 2024-03-31 | $96.00K 10-Q · filed 2025-05-09 | -$550.00K derived: sum of 2 quarters · filed 2025-05-09 | $360.00K derived: sum of 3 quarters · filed 2025-05-09 | $477.00K derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | -$646.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $264.00K derived: sum of 2 quarters · filed 2025-03-31 | $381.00K derived: sum of 3 quarters · filed 2025-03-31 | $464.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $910.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.03M derived: sum of 2 quarters · filed 2024-11-14 | $1.11M 10-Q · filed 2024-11-14 | $230.00K 10-Q · filed 2023-11-14 | $1.11M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $200.00K 10-Q · filed 2023-08-14 | $203.00K derived: sum of 3 quarters · filed 2024-03-08 | $286.00K derived: sum of 4 quarters · filed 2024-03-08 | |
| 2023-03-31 | $83.00K 10-Q · filed 2023-05-11 | $86.00K derived: sum of 2 quarters · filed 2024-03-08 | $169.00K derived: sum of 3 quarters · filed 2024-03-08 | $195.00K derived: sum of 4 quarters · filed 2024-03-08 | |
| 2022-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $86.00K derived: sum of 2 quarters · filed 2024-03-08 | $112.00K derived: sum of 3 quarters · filed 2024-03-08 | $138.00K 10-K · filed 2024-03-08 | |
| 2022-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $109.00K derived: sum of 2 quarters · filed 2023-11-14 | $135.00K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $52.00K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $26.00K 10-Q · filed 2023-05-11 | ||||
| 2021-09-30 | $148.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |